{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:38:59Z","timestamp":1782275939277,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study investigates the patterns of PET-positive lymph nodes (LNs) in anal cancer. The aim was to provide information that could inform future anal cancer radiotherapy contouring guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The baseline [18F]-FDG PET-CTs of 190 consecutive anal cancer patients were retrospectively assessed. LNs with a Deauville score (DS) of \u22653 were defined as PET-positive. Each PET-positive LN was allocated to a LN region and a LN sub-region; they were then mapped on a standard anatomy reference CT. The association between primary tumor localization and PET-positive LNs in different regions were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>PET-positive LNs (<jats:italic>n<\/jats:italic>\u2009=\u2009412) were identified in 103 of 190 patients (54%). Compared to anal canal tumors with extension into the rectum, anal canal tumors with perianal extension more often had inguinal (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and less often perirectal (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and internal iliac (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) PET-positive LNs. Forty-two patients had PET-positive LNs confined to a solitary region, corresponding to first echelon nodes. The most common solitary LN region was inguinal (25 of 42; 60%) followed by perirectal (26%), internal iliac (10%), and external iliac (2%). No PET-positive LNs were identified in the ischiorectal fossa or in the inguinal area located posterolateral to deep vessels. Skip metastases above the bottom of the sacroiliac joint were quite rare. Most external iliac PET-positive LNs were located posterior to the external iliac vein; only one was located in the lateral external iliac sub-region.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results support some specific modifications to the elective clinical target volume (CTV) in anal cancer. These changes would lead to reduced volumes of normal tissue being irradiated, which could contribute to a reduction in radiation side-effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08187-8","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T12:03:36Z","timestamp":1619093016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Patterns of pathologic lymph nodes in anal cancer: a PET-CT-based analysis with implications for radiotherapy treatment volumes"],"prefix":"10.1186","volume":"21","author":[{"given":"Anna","family":"Frennered","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Scherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Buchwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Johnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Zackrisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Tr\u00e4g\u00e5rdh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"issue":"8","key":"8187_CR1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/jnci\/djz219","volume":"112","author":"AA Deshmukh","year":"2020","unstructured":"Deshmukh AA, Suk R, Shiels MS, Sonawane K, Nyitray AG, Liu Y, et al. Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001-2015. J Natl Cancer Inst. 2020;112(8):829\u201338. https:\/\/doi.org\/10.1093\/jnci\/djz219.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"8187_CR2","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1016\/j.clcc.2018.10.001","volume":"18","author":"MG Guren","year":"2019","unstructured":"Guren MG, Aagnes B, Nyg\u00e5rd M, Dahl O, M\u00f8ller B. Rising incidence and improved survival of anal squamous cell carcinoma in Norway, 1987-2016. Clin Colorectal Cancer. 2019;18(1):e96\u2013e103. https:\/\/doi.org\/10.1016\/j.clcc.2018.10.001.","journal-title":"Clin Colorectal Cancer"},{"issue":"12","key":"8187_CR3","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1016\/j.vaccine.2011.01.015","volume":"29","author":"F Jin","year":"2011","unstructured":"Jin F, Stein AN, Conway EL, Regan DG, Law M, Brotherton JM, et al. Trends in anal cancer in Australia, 1982-2005. Vaccine. 2011;29(12):2322\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2011.01.015.","journal-title":"Vaccine"},{"issue":"10","key":"8187_CR4","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/1055-9965.EPI-15-0044","volume":"24","author":"MS Shiels","year":"2015","unstructured":"Shiels MS, Kreimer AR, Coghill AE, Darragh TM, Devesa SS. Anal Cancer Incidence in the United States, 1977-2011: distinct patterns by histology and behavior. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1548\u201356.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"35","key":"8187_CR5","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","volume":"30","author":"LL Gunderson","year":"2012","unstructured":"Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB 3rd, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin. J Clin Oncol. 2012;30(35):4344\u201351. https:\/\/doi.org\/10.1200\/JCO.2012.43.8085.","journal-title":"J Clin Oncol"},{"issue":"6","key":"8187_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","volume":"14","author":"RD James","year":"2013","unstructured":"James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial. Lancet Oncol. 2013;14(6):516\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(13)70086-X.","journal-title":"Lancet Oncol"},{"key":"8187_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ctrv.2018.02.001","volume":"65","author":"D Martin","year":"2018","unstructured":"Martin D, Balermpas P, Winkelmann R, Rodel F, Rodel C, Fokas E. Anal squamous cell carcinoma - state of the art management and future perspectives. Cancer Treat Rev. 2018;65:11\u201321. https:\/\/doi.org\/10.1016\/j.ctrv.2018.02.001.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"8187_CR8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3109\/0284186X.2013.770599","volume":"52","author":"AG Bentzen","year":"2013","unstructured":"Bentzen AG, Balteskard L, Wander\u00e5s EH, Frykholm G, Wilsgaard T, Dahl O, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol. 2013;52(4):736\u201344.","journal-title":"Acta Oncol"},{"issue":"1","key":"8187_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","volume":"86","author":"LA Kachnic","year":"2013","unstructured":"Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86(1):27\u201333. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.09.023.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"8187_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.radonc.2014.04.013","volume":"111","author":"R Glynne-Jones","year":"2014","unstructured":"Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014;111(3):330\u20139. https:\/\/doi.org\/10.1016\/j.radonc.2014.04.013.","journal-title":"Radiother Oncol"},{"key":"8187_CR11","unstructured":"The Swedish national care program for anal cancer (in Swedish). https:\/\/kunskapsbanken.cancercentrum.se\/diagnoser\/analcancer\/vardprogram\/. Accessed 10 Aug 2020."},{"issue":"1080","key":"8187_CR12","doi-asserted-by":"publisher","first-page":"20170370","DOI":"10.1259\/bjr.20170370","volume":"90","author":"A Mahmud","year":"2017","unstructured":"Mahmud A, Poon R, Jonker D. PET imaging in anal canal cancer: a systematic review and meta-analysis. Br J Radiol. 2017;90(1080):20170370. https:\/\/doi.org\/10.1259\/bjr.20170370.","journal-title":"Br J Radiol"},{"issue":"3","key":"8187_CR13","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ijrobp.2008.08.070","volume":"74","author":"RJ Myerson","year":"2009","unstructured":"Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74(3):824\u201330. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.08.070.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"8187_CR14","doi-asserted-by":"publisher","unstructured":"Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, et al. Australasian gastrointestinal trials group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1455\u201362. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.12.058.","DOI":"10.1016\/j.ijrobp.2011.12.058"},{"key":"8187_CR15","unstructured":"The Norweigan national care program for anal cancer (in Norweigan). https:\/\/www.helsedirektoratet.no\/retningslinjer\/analkreft-handlingsprogram\/Analkreft%20-%20Nasjonalt%20handlingsprogram%20med%20retningslinjer%20for%20diagnostikk,%20behandling%20og%20oppf%C3%B8lging.pdf\/_\/attachment\/inline\/06408501-5e87-4e0f-8249-d84877f4fca8:eea588d8f71754f56b2a83ab1a7355439f4fb43f\/Analkreft%20-%20Nasjonalt%20handlingsprogram%20med%20retningslinjer%20for%20diagnostikk,%20behandling%20og%20oppf%C3%B8lging.pdf. Accessed 10 Aug 2020."},{"key":"8187_CR16","unstructured":"The UK national guidance for IMRT in anal cancer. http:\/\/analimrtguidance.co.uk\/national-anal-imrt-guidance-v3.pdf. Accessed 10 Aug 2020."},{"key":"8187_CR17","doi-asserted-by":"publisher","unstructured":"Shakir R, Adams R, Cooper R, Downing A, Geh I, Gilbert D, et al. Patterns and predictors of relapse following Chemoradiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2020;106(2):329\u201339. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.10.016.","DOI":"10.1016\/j.ijrobp.2019.10.016"},{"issue":"Suppl 1","key":"8187_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","volume":"44","author":"SF Barrington","year":"2017","unstructured":"Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):97\u2013110. https:\/\/doi.org\/10.1007\/s00259-017-3690-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"8187_CR19","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257\u201360. https:\/\/doi.org\/10.1080\/10428190903040048.","journal-title":"Leuk Lymphoma"},{"key":"8187_CR20","doi-asserted-by":"crossref","unstructured":"Nilsson MP, Nilsson ED, Johnsson A, Leon O, Gunnlaugsson A, Scherman J. Patterns of recurrence in anal cancer: a detailed analysis. Radiat Oncol. 2020;15(1):125.","DOI":"10.1186\/s13014-020-01567-7"},{"key":"8187_CR21","doi-asserted-by":"publisher","unstructured":"Garda AE, Navin PJ, Merrell KW, Martenson JA, Neben Wittich MA, Haddock MG, et al. Patterns of inguinal lymph node metastases in anal canal cancer and recommendations for elective clinical target volume (CTV) delineation. Radiother Oncol. 2020;149:128\u201333. https:\/\/doi.org\/10.1016\/j.radonc.2020.05.018.","DOI":"10.1016\/j.radonc.2020.05.018"},{"key":"8187_CR22","doi-asserted-by":"publisher","unstructured":"Dapper H, Schiller K, Munch S, Peeken JC, Borm K, Weber W, et al. Have we achieved adequate recommendations for target volume definitions in anal cancer? A PET imaging based patterns of failure analysis in the context of established contouring guidelines. BMC Cancer. 2019;19(1):742. https:\/\/doi.org\/10.1186\/s12885-019-5970-0.","DOI":"10.1186\/s12885-019-5970-0"},{"key":"8187_CR23","doi-asserted-by":"publisher","unstructured":"Pa\u00f1o B, Sebasti\u00e0 C, Bu\u00f1esch L, Mestres J, Salvador R, Mac\u00edas NG, et al. Pathways of lymphatic spread in male urogenital pelvic malignancies. Radiographics. 2011;31(1):135\u201360. https:\/\/doi.org\/10.1148\/rg.311105072.","DOI":"10.1148\/rg.311105072"},{"issue":"1","key":"8187_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s13014-018-1174-z","volume":"13","author":"H Dapper","year":"2018","unstructured":"Dapper H, Oechsner M, Hirche C, Munch S, Sauter C, Borm K, et al. Dosimetric comparison of different radiation techniques (IMRT vs. 3-dimensional) of the \"true\" (deep) ano-inguinal lymphatic drainage of anal cancer patients. Radiat Oncol. 2018;13(1):227.","journal-title":"Radiat Oncol"},{"issue":"2","key":"8187_CR25","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/j.ijrobp.2011.12.062","volume":"83","author":"AG Bentzen","year":"2012","unstructured":"Bentzen AG, Guren MG, Wanderas EH, Frykholm G, Tveit KM, Wilsgaard T, et al. Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort. Int J Radiat Oncol Biol Phys. 2012;83(2):e173\u201380. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.12.062.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"8187_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.radonc.2008.07.023","volume":"89","author":"MJ Vilarino-Varela","year":"2008","unstructured":"Vilarino-Varela MJ, Taylor A, Rockall AG, Reznek RH, Powell ME. A verification study of proposed pelvic lymph node localisation guidelines using nanoparticle-enhanced magnetic resonance imaging. Radiother Oncol. 2008;89(2):192\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2008.07.023.","journal-title":"Radiother Oncol"},{"issue":"4","key":"8187_CR27","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00330-017-5026-2","volume":"28","author":"RGH Beets-Tan","year":"2018","unstructured":"Beets-Tan RGH, Lambregts DMJ, Maas M, Bipat S, Barbaro B, Curvo-Semedo L, et al. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol. 2018;28(4):1465\u201375. https:\/\/doi.org\/10.1007\/s00330-017-5026-2.","journal-title":"Eur Radiol"},{"issue":"8","key":"8187_CR28","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ejso.2007.11.013","volume":"34","author":"S Gretschel","year":"2008","unstructured":"Gretschel S, Warnick P, Bembenek A, Dresel S, Koswig S, String A, et al. Lymphatic mapping and sentinel lymph node biopsy in epidermoid carcinoma of the anal canal. Eur J Surg Oncol. 2008;34(8):890\u20134. https:\/\/doi.org\/10.1016\/j.ejso.2007.11.013.","journal-title":"Eur J Surg Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08187-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08187-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08187-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T12:06:38Z","timestamp":1619093198000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08187-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8187"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08187-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"assertion":[{"value":"19 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and was approved by the Regional Ethical Review Board in Lund, and by the Swedish Ethical Review Authority (Dnr 2013\/742, Dnr 2019\/02669). The need for informed consent was waived by the Regional Ethical Review Board in Lund (Dnr 2013\/742), given the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"447"}}